Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHSBT's Clinical Biotechnology Centre has a requirement for specifying the user requirement for HEK293-derived production cell line for the GMP-production of viral vectors and other recombinant proteins. The CBC has an MHRA licence for the manufacture of investigational medicinal gene therapy and recombinant protein products for use in clinical trials. In order to manufacture GMP-grade viral vectors and recombinant proteins for clinical trials, a GMP-qualified producer cell line is required
No supplier information available.